- Home
- PPT vs ABEO Comparison
PPT vs ABEO Comparison
Compare PPT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPT
- ABEO
- Stock Information
- Founded
- PPT 1988
- ABEO 1974
- Country
- PPT United States
- ABEO United States
- Employees
- PPT N/A
- ABEO N/A
- Industry
- PPT Finance Companies
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- PPT Finance
- ABEO Health Care
- Exchange
- PPT Nasdaq
- ABEO Nasdaq
- Market Cap
- PPT 356.5M
- ABEO 350.2M
- IPO Year
- PPT N/A
- ABEO 1980
- Fundamental
- Price
- PPT $3.74
- ABEO $5.64
- Analyst Decision
- PPT
- ABEO Strong Buy
- Analyst Count
- PPT 0
- ABEO 6
- Target Price
- PPT N/A
- ABEO $18.17
- AVG Volume (30 Days)
- PPT 156.1K
- ABEO 765.1K
- Earning Date
- PPT 01-01-0001
- ABEO 11-13-2025
- Dividend Yield
- PPT 8.84%
- ABEO N/A
- EPS Growth
- PPT N/A
- ABEO N/A
- EPS
- PPT N/A
- ABEO 0.99
- Revenue
- PPT N/A
- ABEO $400,000.00
- Revenue This Year
- PPT N/A
- ABEO N/A
- Revenue Next Year
- PPT N/A
- ABEO $324.71
- P/E Ratio
- PPT N/A
- ABEO $5.66
- Revenue Growth
- PPT N/A
- ABEO N/A
- 52 Week Low
- PPT $3.25
- ABEO $3.93
- 52 Week High
- PPT $3.72
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- PPT 61.46
- ABEO 30.38
- Support Level
- PPT $3.68
- ABEO $6.53
- Resistance Level
- PPT $3.77
- ABEO $6.95
- Average True Range (ATR)
- PPT 0.03
- ABEO 0.30
- MACD
- PPT 0.00
- ABEO -0.16
- Stochastic Oscillator
- PPT 66.67
- ABEO 7.45
About PPT Putnam Premier Income Trust
Putnam Premier Income Trust is a Massachusetts business trust operating as a non-diversified closed-end management investment company. The fund is currently operating as a diversified fund. Its investment objective is to seek high current income consistent with the preservation of capital by allocating its investments to the U.S. government sector.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.